Who is sponsoring NCT00185510?

NCT00185510 is sponsored by LEO Pharma.

What drugs are being tested in NCT00185510?

Interventions in NCT00185510: Methylprednisolone Aceponate (Advantan, BAY86-4862), Placebo.

What condition does NCT00185510 study?

NCT00185510 studies Dermatitis, Atopic.

Is NCT00185510 still recruiting?

NCT00185510 is currently completed. Last updated 8 June 2023.

Last reviewed 2023-06-08 · How we verify

NCT00185510

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis With Advantan Cream

Completed Phase 4 Last updated 8 June 2023

What this trial tests

Phase 4 trial testing Methylprednisolone Aceponate (Advantan, BAY86-4862) in Dermatitis, Atopic in 250 participants. Completed in 1 June 2006.

Timeline

1 March 2005

Primary endpoint
1 May 2006

1 June 2006

Quick facts

Lead sponsor	LEO Pharma
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	250
Start date	1 March 2005
Primary completion	1 May 2006
Estimated completion	1 June 2006

Drugs / interventions tested

Methylprednisolone Aceponate (Advantan, BAY86-4862) — full drug profile →
Placebo

Conditions studied

Dermatitis, Atopic — all drugs for Dermatitis, Atopic →

Sponsor

LEO Pharma — full company profile →

Who can join

12 and older, any sex, with Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time to relapse in the maintenance phase (MP)
Time frame: Week 16

Sponsor's own description

Purpose of the study: One bothering feature of atopic dermatitis is its relapsing nature. Hence, it is worthwhile to test modes how to efficiently prevent relapses or at least increase the time until the disease recurs. In order to give recommendations to other patients, this study is to scientifically describe efficacy and safety of a given regimen, namely a maintenance therapy with two days a week Advantan.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Strategies for using topical corticosteroids in children and adults with eczema.
Lax SJ, Harvey J, Axon E, Howells L, et al · · 2022 · cited 38× · PMID 35275399 · DOI 10.1002/14651858.cd013356.pub2
Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, Steele L, et al · · 2024 · cited 22× · PMID 39105474 · DOI 10.1002/14651858.cd015064.pub2

Verify or expand the search:

Other recruiting trials for Dermatitis, Atopic

Currently open trials in the same condition.

NCT07230860 — A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
NCT06899204 — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate · recruiting
NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
NCT06881251 — A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) · Phase 2 · active not recruiting
NCT06554847 — Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis · Phase 3 · active not recruiting

Other LEO Pharma trials

Trials by the same sponsor.

NCT07335588 — A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus · Phase 3 · not yet recruiting
NCT07013201 — A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to · Phase 2 · recruiting
NCT06444867 — A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 15896 · Phase 1 · completed
NCT06311682 — A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and · Phase 3 · recruiting
NCT05923099 — A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic De · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00185510 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LEO Pharma
Last refreshed: 8 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00185510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing